6-K: Report of foreign issuer [Rules 13a-16 and 15d-16]

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington. D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR I5d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of May 2004
Novogen Limited
(Translation of registrant's name into English)
140 Wicks Road, North Ryde, NSW, 2113, Australia
(Address of principal executive office)
[Indicate by check mark whether the registrant files or will file
annual
reports under cover of Form 20-F or Form 40-F.
Form 20-F v Form 40-F
[Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934. Yes No
[If "Yes" is marked, indicate below the file number assigned to the
registrant in connection with Rule 12g3-2 (b):
82- ________________ .1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized.
Novogen Limited
(Registrant)
Date 19 May,2004 By /s/Ronald Lea Erratt Company Secretary

ASX MEDIA RELEASE
20 MAY 2004

NOVOGEN PATENT GRANTED IN CANADA

Pharmaceutical company, Novogen, has been granted patent
coverage over its OTC products being sold in Canada.

The patent covers the isoflavone composition of the
products Promensil, Rimostil and Trinovin.
Additionally the patent covers the use of isoflavone
health supplements for the treatment of menopause symptoms.

The CEO of Novogen, Mr. Christopher Naughton, said the
grant of this patent significantly strengthens Novogen's
position in the Canadian market.

"The issue of this Canadian patent will facilitate Novogen
discussions with other companies now engaged in, or
planning to enter the market in which Promensil,
Rimostil and Trinovin compete in Canada" Mr. Naughton said.

This patent (# 2,136,233) covers isoflavones in health
supplement tablets and capsules including those sourced
from red clover and soy.

Novogen uses red clover as the source of the four types
of isoflavones in its products, and has licensed to
Solae LLC ( a joint venture company of DuPont and Bunge),
in most countries of the world including Canada, the
rights to health supplements containing isoflavones
extracted from soy.

The U.S. version of this patent as it relates to soy
has already been granted, and under the license from
Novogen, Solae has commenced patent litigation asserting
infringement against a number of parties in the U.S.

More information on the Novogen group of companies
and their associated technology developments can be
found at www.novogen.com and at www.marshalledwardsinc.com.

Statements included in this press release that are
not historical in nature are forward-looking
statements within the meaning of the safe harbor
provisions of the Private Securities Litigation
Reform Act of 1995. You should be aware that
our actual results could differ materially
from those contained in the forward-looking
statements, which are based on managements current
expectations and are subject to a number of risks
and uncertainties, including, but not limited to,
our failure to successfully commercialize our
product candidates; costs and delays in the development
and/or FDA approval, or the failure to obtain such
approval, of our product candidates; uncertainties
in clinical trial results; our inability to maintain
or enter into, and the risks resulting from our
dependence upon, collaboration or contractual arrangements
necessary for the development, manufacture, commercialization,
marketing, sales and distribution of any products;
competitive factors; our inability to protect our
patents or proprietary rights and obtain necessary
rights to third party patents and intellectual property
to operate our business; our inability to operate our
business without infringing the patents and proprietary
rights of others; general economic conditions; the
failure of any products to gain market acceptance;
our inability to obtain any additional required
financing; technological changes; government
regulation; changes in industry practice; and
one-time events. We do not intend to update
any of these factors or to publicly announce
the results of any revisions to these
forward-looking statements.

CONTACT: US-Australia: Mr Christopher Naughton,
CEO, Marshall Edwards, Inc., + 61.2.9878 0088